Readme.rtf

{\rtf1\ansi\ansicpg1252\cocoartf2868
\cocoatextscaling0\cocoaplatform0{\fonttbl\f0\fswiss\fcharset0 Helvetica;\f1\froman\fcharset0 Times-Roman;\f2\froman\fcharset0 Times-Bold;
}
{\colortbl;\red255\green255\blue255;\red0\green0\blue0;}
{\*\expandedcolortbl;;\cssrgb\c0\c0\c0;}
\paperw11900\paperh16840\margl1440\margr1440\vieww11520\viewh8400\viewkind0
\deftab720
\pard\pardeftab720\sl456\partightenfactor0

\f0\fs42\fsmilli21333 \cf2 \expnd0\expndtw0\kerning0
Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: Phase I/II ICRA trial
\f1\fs24  
\f2\b\fs48 \cf0 \outl0\strokewidth0 \strokec2 \
\pard\pardeftab720\sa240\partightenfactor0

\f1\b0\fs24 \cf0 This repository contains the code to reproduce the findings from the study 'Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: Phase I/II ICRA trial' manuscript (under review in Nature Communications ).\
Source data to reproduce the findings from the manuscript is in data/ and code to reproduce the manuscript figures in code/.\
}